Mavenir in Collaboration with Intel Delivers Optimised Performance and Power Efficiency for 4G and 5G Open vRAN Solution
24.2.2024 14:37:00 EET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces availability of its cutting-edge Open vRAN solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost – delivering a cloud-native, high-performance and energy-efficient solution for latency-sensitive and compute-intensive mobile network applications. The move to Intel’s recent processors for vRAN marks the latest solution optimisation for Mavenir, which has driven Open RAN momentum through three generations of Intel Xeon Scalable processors.
Mavenir's Open vRAN solution, powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost, offers an exceptional suite of performance, functionality, and integrated artificial intelligence (AI) and machine learning (ML) application for the next generation 4G and 5G networks. Mavenir has built a close and long-standing technology collaboration with Intel, and the adoption of Intel’s processors enables the development of more efficient and cost-effective RANs. These optimisations are being achieved through the availability of more processing power with higher capacity, resulting in reduction of number of cores or servers needed per cell site.
Mavenir's Open vRAN solution comprises the virtualised distributed Unit (vDU) and the centralised unit (vCU), supporting all mobile network generations (2G, 4G, 5G) and providing a complete baseband unit (BBU) functionality. The solution is cloud-native and easily deployable on Intel architecture-based private, hybrid, or public clouds. The Mavenir vDU incorporates Intel’s FlexRAN reference software, which utilises modular, virtualised control functions across well-defined interfaces that allow flexible and programmable control of the layer 1 wireless infrastructure.
The fully integrated vRAN acceleration feature of 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost eliminates the need for an external acceleration card and delivers up to 2x capacity increase with an additional 20% power savings1 versus the previous generation processor for applications like massive MIMO (mMIMO). This fully integrated solution allows Mobile Network Operators (MNOs) to deploy cloud-native, energy-efficient and AI-driven RAN solutions at a significantly lower cost.
Mavenir's pioneering Open vRAN solution has driven significant industry progress for Open RAN technology, and made Open RAN a mainstream consideration for all operators expanding their 4G and 5G networks, whether building new networks from scratch or upgrading existing ones. The combination sets the stage for more significant advances in next-generation O-RANs including dramatic energy savings, RAN slice assurance, AI/ML-powered SLAs, expanded RAN capacity, and optimised functionality splits.
BG Kumar, President, Access Networks, Platforms and Digital Enablement for Mavenir commented: “Mavenir values our ongoing collaboration with Intel, which is leading the industry in driving forward high-performance and sustainable Open vRAN solutions for 4G and 5G networks. Mavenir’s integrated solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost optimises the Open vRAN solution offerings even further– giving CSPs worldwide the ability to deploy cloud-native, energy-efficient, and cost-effective AI/ML powered RAN infrastructure built on world-class technology.”
Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel said: “Operators’ journey to design and deploy new networks drives a key set of technology needs and challenges to be addressed. Mavenir’s solution leverages the best features of Intel’s 4th Gen Intel Xeon platform to provide operators a flexible solution with advanced functionalities to meet the diverse needs of both greenfield and brownfield operators.”
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realise the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
____________________________
1 For workloads and configurations visit www.Intel.com/PerformanceIndex. Results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223458554/en/
Contact information
Mavenir PR Contact:
Emmanuela Spiteri
PR@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom